KR101808398B1 - 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 - Google Patents

스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 Download PDF

Info

Publication number
KR101808398B1
KR101808398B1 KR1020157031951A KR20157031951A KR101808398B1 KR 101808398 B1 KR101808398 B1 KR 101808398B1 KR 1020157031951 A KR1020157031951 A KR 1020157031951A KR 20157031951 A KR20157031951 A KR 20157031951A KR 101808398 B1 KR101808398 B1 KR 101808398B1
Authority
KR
South Korea
Prior art keywords
clfa
protein
crm
staphylococcus aureus
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157031951A
Other languages
English (en)
Korean (ko)
Other versions
KR20150129071A (ko
Inventor
라크쉬미 칸드케
아키히사 노노야마
타마라 샤퍼 핫쥐
샌딥 니마
Original Assignee
와이어쓰 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 엘엘씨 filed Critical 와이어쓰 엘엘씨
Publication of KR20150129071A publication Critical patent/KR20150129071A/ko
Application granted granted Critical
Publication of KR101808398B1 publication Critical patent/KR101808398B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020157031951A 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 Expired - Fee Related KR101808398B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22
US61/426,476 2010-12-22
PCT/IB2011/055883 WO2012085872A2 (en) 2010-12-22 2011-12-21 Stable immunogenic compositions of staphylococcus aureus antigens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137018851A Division KR20130114210A (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물

Publications (2)

Publication Number Publication Date
KR20150129071A KR20150129071A (ko) 2015-11-18
KR101808398B1 true KR101808398B1 (ko) 2017-12-12

Family

ID=45444677

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157031951A Expired - Fee Related KR101808398B1 (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물
KR1020137018851A Ceased KR20130114210A (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137018851A Ceased KR20130114210A (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물

Country Status (18)

Country Link
US (1) US20130259896A1 (enExample)
EP (2) EP3150222B1 (enExample)
JP (1) JP6097478B2 (enExample)
KR (2) KR101808398B1 (enExample)
CN (1) CN103826656B (enExample)
AU (1) AU2011346535B2 (enExample)
BR (1) BR112013016153A2 (enExample)
CA (1) CA2819120C (enExample)
DK (2) DK3150222T3 (enExample)
ES (2) ES2769425T3 (enExample)
HU (2) HUE033072T2 (enExample)
IL (1) IL226793B (enExample)
MX (1) MX350170B (enExample)
PL (2) PL3150222T3 (enExample)
PT (2) PT2654784T (enExample)
RU (1) RU2570730C2 (enExample)
SI (2) SI2654784T1 (enExample)
WO (1) WO2012085872A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
TWI505834B (zh) 2009-06-22 2015-11-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
EP3170508B1 (en) * 2010-06-04 2019-11-13 Wyeth LLC Vaccine formulations
CN103561762A (zh) * 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
JP2016540764A (ja) * 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
AU2015245530B2 (en) * 2014-04-10 2019-10-03 Asit Biotech S.A. HSP-free allergen preparation
US20200360500A1 (en) * 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
JP2023512446A (ja) * 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158334A1 (en) 2001-07-26 2005-07-21 Mario Contorni Vaccines comprising aluminium adjuvants and histidine
WO2006032472A2 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2007113223A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007113222A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2008057550A2 (en) * 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
EP1034277B1 (en) 1997-11-26 2012-06-27 Inhibitex, Inc. Extracellular matrix-binding proteins from Staphylococcus aureus
KR100644953B1 (ko) * 1998-08-31 2006-11-10 인히비텍스, 인코포레이티드 다성분 백신
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
CA2450939C (en) 2001-06-15 2012-11-06 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
US9296795B2 (en) 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
KR101695800B1 (ko) 2008-03-05 2017-02-22 사노피 파스퇴르 항원보강제 함유 백신 조성물의 안정화 방법
BRPI1015567A2 (pt) * 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158334A1 (en) 2001-07-26 2005-07-21 Mario Contorni Vaccines comprising aluminium adjuvants and histidine
WO2006032472A2 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2007113223A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007113222A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2008057550A2 (en) * 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMBO J. 21(24): 6660-6672(2002.12.16.)*
Vaccine 27(33): 4388-4401(2009.05.28.)*

Also Published As

Publication number Publication date
JP2012136518A (ja) 2012-07-19
DK3150222T3 (da) 2020-01-27
PL3150222T3 (pl) 2020-05-18
WO2012085872A2 (en) 2012-06-28
CA2819120A1 (en) 2012-06-28
HK1197370A1 (en) 2015-01-16
BR112013016153A2 (pt) 2017-07-11
PT3150222T (pt) 2020-02-03
CN103826656B (zh) 2015-08-26
AU2011346535A1 (en) 2013-06-13
ES2614815T3 (es) 2017-06-02
EP2654784A2 (en) 2013-10-30
CA2819120C (en) 2016-07-05
SI2654784T1 (sl) 2017-01-31
RU2570730C2 (ru) 2015-12-10
KR20130114210A (ko) 2013-10-16
RU2013128277A (ru) 2015-01-27
KR20150129071A (ko) 2015-11-18
WO2012085872A3 (en) 2012-08-30
US20130259896A1 (en) 2013-10-03
MX350170B (es) 2017-08-28
EP2654784B1 (en) 2016-12-07
IL226793B (en) 2019-02-28
EP3150222A1 (en) 2017-04-05
PT2654784T (pt) 2017-02-13
EP3150222B1 (en) 2019-11-27
DK2654784T3 (en) 2017-02-13
ES2769425T3 (es) 2020-06-25
JP6097478B2 (ja) 2017-03-15
SI3150222T1 (sl) 2020-02-28
HUE047263T2 (hu) 2020-04-28
CN103826656A (zh) 2014-05-28
HUE033072T2 (hu) 2017-11-28
MX2013006960A (es) 2013-07-15
AU2011346535B2 (en) 2015-09-24
PL2654784T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
KR101808398B1 (ko) 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물
KR101486122B1 (ko) 스타필로코커스 아우레우스 항원의 면역원성 조성물
JP6393804B2 (ja) 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
RU2672053C2 (ru) Способ гликоконъюгации
US9561269B2 (en) Neisseria meningitidis compositions and methods thereof
US10829521B2 (en) Neisseria meningitidis composition and methods thereof
KR20130079536A (ko) 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
HK1197370B (en) Stable immunogenic compositions of staphylococcus aureus antigens
HK1241717A1 (en) Immunogenic compositions of staphylococcus aureus antigens
HK1171653A (en) Immunogenic compositions of staphylococcus aureus antigens

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20231207

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231207

St.27 status event code: N-4-6-H10-H13-oth-PC1903